Insilico Medicine has deepened its alliance with China Medical System Holdings through a new AI-enabled drug discovery program targeting a high-volume central nervous system indication with a novel mechanism of action identified by its PandaOmics platform. Under the latest agreement, Insilico will co-develop the candidate with CMS, combining its generative AI and automated discovery capabilities with CMS’s clinical development and commercialization infrastructure, and is eligible for up to about RMB 1.2 billion in milestones plus royalties, creating a potentially meaningful future revenue stream.
The new CNS program comes just three months after the companies’ initial collaboration, signaling early operational success and strategic alignment across the R&D and commercialization value chain. Insilico’s Co-CEO and CSO, Feng Ren, said the partnership has been “seamless and productive,” emphasizing that PandaOmics’ mechanism-of-action discovery is intended to shorten the path from proof of concept to clinical-stage assets, while CMS highlighted Insilico’s productivity in AI drug discovery and the fit with its own regulatory and market reach. As a newly listed company on the Hong Kong Stock Exchange (03696.HK), Insilico is leveraging such alliances to monetize its AI platforms across high-burden disease areas, positioning itself as a key AI-driven partner for mass-market indications while potentially de-risking capital needs for later-stage development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.